FREQ Frequency Therapeutics Inc.

FDA Catalyst Company
1.34
+0.03  (+2%)
Previous Close 1.31
Open 1.36
52 Week Low 1.16
52 Week High 10.9
Market Cap $46,868,388
Shares 34,976,409
Float 32,243,206
Enterprise Value $-29,154,017
Volume 660,096
Av. Daily Volume 785,796
Live cash est $88,666,444,222
Cash Burn N/A
No. Mths Cash 12
Insiders % 0.2
Total debt to equity 4.35
Earnings Date 01/01/2001
EPS EST. 1.82
EPS PRIOR. 1.82
EPS 1.82
Rev guidance $10,459,000,000

Biotech Analyst Ratings

Analyst Action Rating Now PT Prior PT Now Last Updated
B. Riley Securities Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 03/23/2022
Goldman Sachs Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 09/22/2021
Oppenheimer Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 03/24/2021
JP Morgan Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 01/27/2021
Oppenheimer Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 07/14/2020
JP Morgan Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 05/18/2020
JP Morgan Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 03/27/2020

Latest News

  1. FX-322-208 Phase 2b Study in Individuals with Acquired Sensorineural Hearing Loss Remains on Track for a Readout in Q4 2022 or Q1 2023

    Reports Cash and Cash Equivalents of $124.8M, Providing Runway into 2024; Funds Enable Company to Meet Multiple Clinical Milestones for Programs Targeting Hearing Loss and Multiple Sclerosis

    Frequency Therapeutics, Inc. (NASDAQ:FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person's innate regenerative potential to restore function, today announced business updates and financial results for the first quarter ended March 31, 2022.

    "Frequency continues to make important progress executing our pipeline of therapeutic programs for hearing loss and remyelination…

    View Full Article
  2. Frequency Therapeutics, Inc. (NASDAQ:FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person's innate regenerative potential to restore function, today announced that Chief Scientific Officer Dr. Christopher Loose and Vice President of Discovery Biology Dr. Sanjay Magavi will participate in a fireside presentation at the B. Riley Securities' Neuro & Ophthalmology Conference on April 28, 2022 at 3:30 pm ET.

    A live webcast of both the panel and presentation can be accessed on the Investors & Media section of Frequency's website and a replay will be posted following the event.

    About Frequency Therapeutics

    Frequency Therapeutics is leading a new category in regenerative medicine that aims…

    View Full Article
  3. Company Reports Steady Enrollment for FX-322-208 Phase 2b Study in Individuals with Sudden and Noise-Induced Sensorineural Hearing Loss; Topline Results Anticipated in Q4 2022 or Q1 2023

    Continued Progress on Second Program for Hearing Restoration, FX-345; Phase 1b Start Anticipated in H2 2022

    Advances Lead Optimization for Remyelination Program in Multiple Sclerosis (MS); Selection of Lead Clinical Candidate in 2022; IND Planned in 2023

    Frequency Therapeutics, Inc. (NASDAQ:FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person's innate regenerative potential to restore function, today announced business updates and financial results for the fourth quarter and full year ended December…

    View Full Article
  4. Frequency Therapeutics, Inc. (NASDAQ:FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person's innate regenerative potential to restore function, today announced that Chief Executive Officer David L. Lucchino will participate in two upcoming investor conferences:

    • Cowen 42nd Annual Health Care Conference: Corporate Panel Discussion - Auditory and Ophthalmology, March 7, 2022, 2:10 p.m. to 3:10 p.m. EST
    • Oppenheimer 32nd Annual Healthcare Conference: Company Overview Presentation, Wednesday, March 16, 2022, 3:20 p.m. to 3:50 p.m. EST

    A live webcast of both the panel and presentation can be accessed on the investors section of Frequency's website, investors.frequencytx.com. A replay of…

    View Full Article
  5. Company to Review Milestones for its Phase 2b Study of FX-322, the Near-Term Clinical Plan for its Second Hearing Restoration Asset, FX-345, and Selection of a Lead Candidate for its Novel Multiple Sclerosis Program that Has Shown Potent Pre-Clinical Data

    Frequency Therapeutics, Inc. (NASDAQ:FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person's innate regenerative potential to restore function, today announced that Chief Executive Officer David L. Lucchino will present a Company overview at the 40th Annual J.P. Morgan Healthcare Conference.

    Mr. Lucchino's presentation will take place on January 13th at 10:30 a.m. ET and will be followed by a question-and-answer session immediately…

    View Full Article
View All Frequency Therapeutics Inc. News